BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol 2015;2:e974463. [PMID: 27308423 DOI: 10.4161/23723556.2014.974463] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Jin JO, Puranik N, Bui QT, Yadav D, Lee PC. The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer. Int J Mol Sci 2021;22:9629. [PMID: 34502538 DOI: 10.3390/ijms22179629] [Reference Citation Analysis]
2 Nam SM, Jeon YJ. Proteostasis In The Endoplasmic Reticulum: Road to Cure. Cancers (Basel) 2019;11:E1793. [PMID: 31739582 DOI: 10.3390/cancers11111793] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
3 Manic G, Obrist F, Sistigu A, Vitale I. Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol 2015;2:e1012976. [PMID: 27308506 DOI: 10.1080/23723556.2015.1012976] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 12.0] [Reference Citation Analysis]
4 Patatsos K, Shekhar TM, Hawkins CJ. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma. Vet Comp Oncol 2018;16:544-53. [PMID: 29998615 DOI: 10.1111/vco.12413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
5 Das B, Neilsen BK, Fisher KW, Gehring D, Hu Y, Volle DJ, Kim HS, McCall JL, Kelly DL, MacMillan JB, White MA, Lewis RE. A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells. Sci Rep 2018;8:3770. [PMID: 29491475 DOI: 10.1038/s41598-018-22090-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Sidor-Kaczmarek J, Cichorek M, Spodnik JH, Wójcik S, Moryś J. Proteasome inhibitors against amelanotic melanoma. Cell Biol Toxicol 2017;33:557-73. [PMID: 28281027 DOI: 10.1007/s10565-017-9390-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
7 Heitmeier T, Sydykov A, Lukas C, Vroom C, Korfei M, Petrovic A, Klingel K, Günther A, Eickelberg O, Weissmann N, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT, Meiners S, Kosanovic D. Altered proteasome function in right ventricular hypertrophy. Cardiovasc Res 2020;116:406-15. [PMID: 31020333 DOI: 10.1093/cvr/cvz103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 El Yaagoubi OM, Oularbi L, Bouyahya A, Samaki H, El Antri S, Aboudkhil S. The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-κB signal transduction. Cancer Biol Ther 2021;:1-14. [PMID: 34583610 DOI: 10.1080/15384047.2021.1978785] [Reference Citation Analysis]
9 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
10 Leonardo-sousa C, Carvalho AN, Guedes RA, Fernandes PMP, Aniceto N, Salvador JAR, Gama MJ, Guedes RC. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance. Molecules 2022;27:2201. [DOI: 10.3390/molecules27072201] [Reference Citation Analysis]
11 Dato AD, Cunsolo A, Persico M, Santoro AM, D'Urso A, Milardi D, Purrello R, Stefanelli M, Paolesse R, Tundo GR, Sbardella D, Fattorusso C, Coletta M. Electrostatic Map Of Proteasome α-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding. Sci Rep 2017;7:17098. [PMID: 29213119 DOI: 10.1038/s41598-017-17008-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omedè P, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood 2019;133:156-67. [PMID: 30455381 DOI: 10.1182/blood-2018-05-850826] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
13 Masuelli L, Granato M, Benvenuto M, Mattera R, Bernardini R, Mattei M, d'Amati G, D'Orazi G, Faggioni A, Bei R, Cirone M. Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice. Oncoimmunology 2017;6:e1356151. [PMID: 29147611 DOI: 10.1080/2162402X.2017.1356151] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
14 Xu D, Liang SQ, Yang H, Lüthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. Br J Cancer 2018;119:65-75. [PMID: 29921948 DOI: 10.1038/s41416-018-0145-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
15 Iconomou M, Saunders DN. Systematic approaches to identify E3 ligase substrates. Biochem J 2016;473:4083-101. [PMID: 27834739 DOI: 10.1042/BCJ20160719] [Cited by in Crossref: 85] [Cited by in F6Publishing: 49] [Article Influence: 17.0] [Reference Citation Analysis]